Auro Labs.

Auro_Labs.29 Apr 2024

Pharmaceuticals

₹

+1.50 (+0.71%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Auro Labs.

Auro Labs.

Pharmaceuticals

Auro_Labs.29 Apr 2024

₹

+1.50 (+0.71%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
23-Sep-2023	BC	We wish to inform you that the Shareholders of the Company at the 34th Annual General Meeting approved reappointment of Mr. Kiran Suresh Kulkarni as a Whole TIme Director of the Company w.e.f May 24,	24-May-2024
30-Mar-2024	BC	We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors, in their meeting held today i.e Saturday March 30, 2024, appointed Mr. Mahendr	01-Apr-2024
30-Mar-2024	BC	Intimation of tenure completion of Mr. Kailash Chand Bubna (DIN: 01877773) as Independent Director of the Company w.e.f closing of business hours on March 31, 2024	31-Mar-2024
30-Mar-2024	BC	We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors, in their meeting held today i.e Saturday March 30, 2024, appointed Mr. Mahendr	30-Mar-2024
26-Mar-2024	BC	Siddhartha Deorah HUF	21-Mar-2024

No Rights has been declared by Auro_Labs.

Book Closure

Record Date	Split Date	Purpose
24-May-2024	-	We wish to inform you that the Shareholders of the Company at the 34th Annual General Meeting approved reappointment of Mr. Kiran Suresh Kulkarni as a Whole TIme Director of the Company w.e.f May 24,
01-Apr-2024	-	We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors, in their meeting held today i.e Saturday March 30, 2024, appointed Mr. Mahendr
31-Mar-2024	-	Intimation of tenure completion of Mr. Kailash Chand Bubna (DIN: 01877773) as Independent Director of the Company w.e.f closing of business hours on March 31, 2024
30-Mar-2024	-	We wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors, in their meeting held today i.e Saturday March 30, 2024, appointed Mr. Mahendr
21-Mar-2024	-	Siddhartha Deorah HUF

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Auro Laboratories Ltd ₹213.80(+1.50/0.71%)	213.80	+1.50	132.26	230.74	18.40	3.57
Astrazeneca Pharma India Ltd ₹5,550.00(+134.60/2.49%)	5,550.00	+134.60	13,538.50	71.09	84.88	20.67
Bliss GVS Pharma Ltd ₹124.60(+2.00/1.63%)	124.60	+2.00	1,283.51	60.79	18.80	1.31
Cipla Ltd ₹1,409.95(+0.55/0.04%)	1,409.95	+0.55	113,794.25	54.54	34.60	4.40
Abbott India Ltd ₹26,292.15(+427.30/1.65%)	26,292.15	+427.30	54,962.81	15.87	47.98	17.68
Amrutanjan Health Care Ltd ₹711.00(+30.15/4.43%)	711.00	+30.15	1,968.38	13.21	44.73	7.51

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	17.98	13.41	10.18	13.52	15.62	12.56
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	17.98	13.41	10.18	13.52	15.62	12.56
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.42	0.32	0.36	0.62	0.43	-0.16
Total Income	18.40	13.73	10.55	14.14	16.05	12.40
Total Expenditure	13.90	10.38	9.03	11.17	15.18	11.54
PBIDT	4.50	3.35	1.52	2.97	0.88	0.86
Interest	0.44	0.35	0.27	0.13	0.10	0.32
PBDT	4.06	3.00	1.25	2.84	0.78	0.54
Depreciation	0.27	0.27	0.27	0.30	0.27	0.25
Tax	1.05	0.76	0.27	0.75	0.14	0.08
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Reported Profit After Tax	2.73	1.97	0.71	1.78	0.37	0.21
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	2.73	1.97	0.71	1.78	0.37	0.21

EPS (Unit Curr.)	4.39	3.16	1.14	2.86	0.59	0.34
EPS (Adj) (Unit Curr.)	4.39	3.16	1.14	2.86	0.59	0.34
Calculated EPS (Unit Curr.)	4.39	3.16	1.14	2.86	0.59	0.34
Calculated EPS (Adj) (Unit Curr.)	4.39	3.16	1.14	2.86	0.59	0.34
Calculated EPS (Ann.) (Unit Curr.)	17.55	12.63	4.54	11.44	2.35	1.35
Calculated EPS (Adj) (Ann.) (Unit Curr.)	17.55	12.63	4.54	11.44	2.35	1.35
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	6.23	6.23	6.23	6.23	6.23	6.23
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	25.03	24.98	14.93	21.97	5.63	6.85
PBDTM(%)	22.58	22.37	12.28	21.01	4.99	4.30
PATM(%)	15.18	14.69	6.97	13.17	2.37	1.67

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	6.23	6.23	6.23	6.23	6.23	6.23
Reserves Total	27.97	25.29	22.35	15.27	11.18	6.75
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	34.20	31.52	28.58	21.50	17.41	12.98
Secured Loans	6.01	8.13	1.93	1.81	8.09	9.20
Unsecured Loans	0.40	5.65	1.23	1.35	0.00	0.00
Total Debt	6.41	13.78	3.16	3.16	8.09	9.20
Total Liabilities	40.61	45.30	31.74	24.66	25.50	22.18
APPLICATION OF FUNDS :
Gross Block	25.47	25.39	24.28	23.96	23.26	20.68
Less : Accumulated Depreciation	12.85	11.78	10.73	9.73	8.67	7.66
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	12.62	13.61	13.55	14.23	14.59	13.02
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	7.67	3.68	0.13	0.12	0.12	1.07
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.05	0.05	0.05	0.05	0.05	0.05
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	11.76	4.25	2.55	4.06	3.37	1.49
Sundry Debtors	12.40	13.61	7.30	5.78	8.50	8.37
Cash and Bank	2.42	12.40	14.54	5.68	4.11	2.25
Loans and Advances	9.08	7.36	3.77	2.42	2.73	4.14
Total Current Assets	35.66	37.63	28.15	17.95	18.71	16.26
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	12.67	6.50	7.42	6.04	5.96	6.04
Provisions	1.06	1.51	1.05	0.09	0.50	0.75
Total Current Liabilities	13.73	8.01	8.47	6.13	6.46	6.79
Net Current Assets	21.93	29.62	19.68	11.81	12.26	9.47
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	1.65	1.65	1.68	1.56	1.50	1.44
Net Deferred Tax	-1.65	-1.65	-1.68	-1.56	-1.50	-1.44
Total Assets	40.61	45.30	31.74	24.65	25.51	22.18
Contingent Liabilities	1.92	1.92	1.92	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	12.40	14.54	5.68	4.11	2.25
Net Cash from Operating Activities	3.28	-6.59	12.82	9.30	6.87
Net Cash Used In Investing Activities	-5.08	-5.34	-3.51	-2.21	-3.19
Net Cash Used In Financing Activities	-8.18	9.79	-0.46	-5.52	-1.83
Net Inc./Dec In Cash And Cash Equivalents	-9.98	-2.14	8.85	1.58	1.86
Cash And Cash Equivalents At End Of The Year	2.42	12.40	14.54	5.68	4.11

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

52.15%

FII Shareholding

0.00%

DII Shareholding

0.01%

Public Shareholding

47.84%

**Promoter pledged shareholding 52.15%

About Auro Laboratories Ltd

Auro Laboratories Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 132.26 crores. It has reported a sales of Rs. 17.98 crores and a net profit of Rs. 2.73 crores for the quarter ended December 2018. The company management includes Sharat Deorah, Sharat Deorah,Siddhartha Deorah,Goverdhandas Aggarwal,Kailash Chandra Bubna,Kavita Vijayakant Sharma,Kiran Kulkarni,Sweta Agarwal,Vishal Kailash Chandra Jhunjhunwala (Auro Laboratories Ltd) among others.

Chairman

Sharat Deorah

Registered office

K-56 MIDC Indl Area,Tarapur Boisar,Thane,Maharashtra,401506

FAX :

Background

Incorporation Year1989

Face Value₹10

Market Lot1

How to buy Auro Labs. shares on nse?

To buy Auro Labs. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Auro Labs. share price today?

The Auro Labs. shares price on nse is Rs.213.8 today.

What is the market cap of Auro Labs. shares on BSE ?

The company has a market capitalization of Rs.132.26Cr

What is the PE & PB ratio of Auro Labs. shares ?

PE is 18.4 and PB is 3.57

What is the 52 Week High and Low of Auro Labs. shares?

Auro Labs. stock price high: Rs.227.9 Auro Labs. stock price low: Rs.63